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Introduction
Quinine has been the mainstay of treatment of severe
malaria since the introduction of Cinchona Bark to
European medicine in the 1630s. There is evidence of a
decline in the efﬁcacy of the drug in southeast Asia, in
terms of parasite and fever clearance in uncomplicated
malaria and coma recovery times in severe malaria, but
there is no indication of a corresponding rise in
mortality.1,2 There have been occasional case reports3–5 of
treatment not curing severe malaria, but these reports
are limited by the absence of measurements of plasma
quinine concentrations.6 Quinine, because it can be
relied on, is the only drug recommended for the
treatment of severe malaria throughout Africa, South
America, and most of Asia. But even with prompt
administration of quinine in maximum doses the
mortality of severe malaria remains high. Cerebral
malaria, the most prominent manifestation of severe
malaria, has a treated mortality rate of 15–20%. With
multiple vital organ dysfunction, the mortality rate can
rise above 30%.7,8 Despite many treatment trials, no
intervention has been shown conclusively to reduce
these high ﬁgures. Indeed, no randomised controlled
trial on severe malaria has shown a convincing beneﬁt
for any intervention over standard treatment with
parenteral quinine alone, and many adjuvant
treatments have proved harmful. Quinine has a narrow
therapeutic ratio.8 In the treatment of severe malaria,
parenteral quinine is given either by intramuscular
injection or as slow rate-controlled intravenous
infusions,7–9 since rapid injection results in potentially
lethal hypotension. Intramuscular administration is
painful, and can cause sterile abscesses, sciatic nerve
damage, and predispose to lethal tetanus.10 Blindness
and deafness can follow self poisoning, but these
adverse effects are rare in severe malaria, whereas
quinine induced hyperinsulinaemic hypoglycaemia is a
common and serious complication.7,8,11
The rediscovery of qinghaosu (artemisinin) in China
in 197212 and the subsequent synthesis of artemether
and artesunate have provided highly effective
alternatives to quinine.13 The artemisinin derivatives are
the most rapidly acting and potent of all the antimalarial
drugs. They can be given once daily and are safer and
easier to administer than quinine. Artesunate or
artemether given orally are an essential component of
the combination treatment of uncomplicated
falciparum malaria, which is now accepted as the
treatment of choice.14 In several southeast Asian
countries, parenteral artemisinin derivatives are used in
preference to quinine for severe malaria, but quinine is
still the drug of choice in most of the malaria-affected
regions of the world.7,8
The largest clinical trials done on severe malaria have
been randomised comparisons of artemether and
quinine.15 When these trials began 14 years ago in
Vietnam, the UNICEF-UNDP-World Bank-WHO
Tropical Disease Research Special Programme for
Research and Training in Tropical Diseases (WHO-
TDR) favoured parenteral artemether, and the closely
related compound artemotil, over artesunate. The
results of these trials15,16 showed that although
artemether was safer and easier to use than quinine,
overall survival was not signiﬁcantly different. In
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Artesunate versus quinine for treatment of severe
falciparum malaria: a randomised trial
South East Asian Quinine Artesunate Malaria Trial (SEAQUAMAT) group*
Summary
Background In the treatment of severe malaria, intravenous artesunate is more rapidly acting than intravenous
quinine in terms of parasite clearance, is safer, and is simpler to administer, but whether it can reduce mortality is
uncertain.
Methods We did an open-label randomised controlled trial in patients admitted to hospital with severe falciparum
malaria in Bangladesh, India, Indonesia, and Myanmar. We assigned individuals intravenous artesunate
2·4 mg/kg bodyweight given as a bolus (n=730) at 0, 12, and 24 h, and then daily, or intravenous quinine (20 mg
salt per kg loading dose infused over 4 h then 10 mg/kg infused over 2–8 h three times a day; n=731). Oral
medication was substituted when possible to complete treatment. Our primary endpoint was death from severe
malaria, and analysis was by intention to treat.
Findings We assessed all patients randomised for the primary endpoint. Mortality in artesunate recipients was
15% (107 of 730) compared with 22% (164 of 731) in quinine recipients; an absolute reduction of 34·7% (95% CI
18·5–47·6%; p=0·0002). Treatment with artesunate was well tolerated, whereas quinine was associated with
hypoglycaemia (relative risk 3·2, 1·3–7·8; p=0·009). 
Interpretation Artesunate should become the treatment of choice for severe falciparum malaria in adults. 
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prospectively deﬁned subgroup analyses, artemether
did reduce mortality signiﬁcantly in adults from
southeast Asia, but not in children from Africa.
Findings of studies on the pharmacokinetics of the
artemisinin derivatives suggest that artesunate would
have been a better choice than artemether; artemether
is an oil-based formulation that releases the drug
slowly and erratically from the injection site,17–20
whereas artesunate can be given intravenously and is
absorbed reliably and rapidly after intramuscular
injection with peak concentrations arising within
1 h.20–22 Artesunate and its main active metabolite
dihydroartemisinin have relative in-vitro potency, by
comparison with artemether, of 2·9 and 4·0,
respectively.23 Results of a pilot randomised com-
parison24 of intravenous artesunate and intravenous
quinine in patients with severe malaria (n=113) on the
north-western border of Thailand showed that
mortality was 22% in the quinine group and 12% in the
artesunate group. Our aim was, therefore, to establish
conclusively which, of parenteral artesunate or
parenteral quinine, is the more effective drug for the
treatment of severe malaria.
Methods
Participants
Between June, 2003, and May, 2005, we did a
multicentre, open-label, randomised comparison of
parenteral artesunate and parenteral quinine in patients
admitted to hospital with severe falciparum malaria.
The participating centres (webtable) were located in
Bangladesh, Myanmar (Burma), India, and Indonesia.
Our inclusion criteria were patients’ age older than
2 years, a positive blood antigen stick test for
Plasmodium falciparum histidine rich protein 2 (HRP2;
Paracheck, Orchid Biosystems, Goa, India), and a
diagnosis of severe malaria, according to the admitting
physician. We did not include patients if there was a
convincing history of full treatment with quinine
(40 mg/kg on the ﬁrst day and 30 mg/kg on any
subsequent day) or an artemisinin derivative for more
than 24 h before admission, or if there was known
allergy to one of the artemisinin derivatives or quinine.
All patients, or their attendant relative or guardian,
provided written informed consent, and the study was
approved by every participating institution’s local or
national ethics committee and the Oxford tropical
research ethics committee.
Procedures
Patients with suspected severe malaria were admitted
and examined. We conﬁrmed their diagnosis of malaria
with an HRP2-antigen based rapid test (Paracheck), and
kept an independent sequential record of all patients
assessed. We randomised patients to intravenous
artesunate or quinine. The two-step randomisation was
produced with a computer generated randomisation
list. After informed consent was obtained, we signed
and dated a numbered sealed envelope across the seal,
then opened it to reveal a unique study number. This
number did not indicate the treatment allocation, but
referred to a separate sealed hardcover box, containing
the study drug, case record form, and all disposables
needed for drug administration and blood sampling.
Hence, local investigators were unaware of the allocated
treatment until after the patients had been randomised.
The trial centre, microscopists assessing blood slides,
and data analysts remained unaware of treatment
allocation until the end of the study. We retained all
envelopes, boxes, and records for subsequent inspection
by the study monitors. 
A peripheral blood smear was stored for later
quantitative parasite counting, and blood was taken for
immediate haematocrit and biochemical analysis with
the EC8 card for a handheld battery-operated
biochemical analyser (i-STAT; Abbott, East Windsor,
NJ, USA). This machine provided an immediate
hardcopy readout of biochemical results with time and
date. Treatment was started immediately. All other
aspects of supportive treatment, based on WHO
guidelines,7,8 were unaffected by the trial.
If assigned, artesunate 2·4 mg/kg bodyweight (Guilin
Pharmaceutical Factory, Guangxi, People’s Republic of
China) was given on admission, then at 12 h, 24 h, and
thereafter once daily until oral medication could be
taken reliably. Every 60 mg vial contained anhydrous
artesunic acid, which we dissolved in 1 mL 5% sodium
bicarbonate and then mixed with 5 mL of 5% dextrose
before injecting as a bolus into an indwelling
intravenous cannula. When the patient had recovered
sufﬁciently to take tablets, we administered oral
artesunate 2 mg salt per kg per day to complete a total
course (including parenteral treatment) of 7 days,
providing a total cumulative dose of 17–18 mg/kg. 
Alternatively, quinine dihydrochloride (Government
Pharmaceutical Organisation, Bangkok, Thailand) was
given in a 20 mg/kg loading dose infused over 4 h (in
500 mL 5% dextrose water or 0·9% saline), followed by
10 mg/kg infused over 2–8 h three times a day until
starting oral therapy. When the patient had recovered
sufﬁciently to take tablets, we administered oral quinine
10 mg/kg every 8 h to provide a total quinine course of
7 days. 
We combined both regimens, except in children
younger than age 8 years or pregnant women, with oral
doxycycline 100 mg twice a day for 7 days once the
patient could take oral medication. The hospitals in
Chittagong, Bangladesh, and in Orissa, India, did not
give doxycycline with either study drug.
External monitors regularly inspected the trial sites.
We checked drug content and quality in random
ampoules taken from the purchase lots. The data safety
and monitoring committee chairman also made
periodic checks of clinical and laboratory variables and
See Lancet Online
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other aspects of management to ascertain whether
randomisation was adequate. We replaced any study
centre that enrolled a predominance of non-severe
patients with another centre in the same country. We
entered all data in duplicate into a purpose-designed
database. All malaria slides were read in the reference
laboratories in the Shoklo Malaria Research Unit in
Mae Sot, Thailand, or in the Faculty of Tropical
Medicine, Mahidol University, Bangkok, Thailand. 
Our primary endpoint was death from severe
malaria—ie, in-hospital mortality—and secondary
outcome measures were incidence of neurological
sequelae, combined death or neurological sequelae,
recovery times (times to eat, speak, sit, and discharge),
and development of severe complications.
Statistical analysis 
Our aim was to include 2000 patients with severe
malaria, to be able to show a 33% reduction in mortality
from 12% to 8% with a power of 80% and a conﬁdence
of 95%, allowing a drop out (ineligibility) rate of 5%.
This estimate was based on about half of the enrolled
patients subsequently fulﬁlling modiﬁed WHO criteria
for severe malaria (panel),25 and these patients having a
24% mortality (based on local ﬁgures). We gave all
patients’ data and outcomes to an independent data and
safety monitoring committee whose remit included
advising us to stop the trial if there was evidence beyond
reasonable doubt that the results would change clinical
practice. The trial was stopped on May 11, 2005.
We did the analysis according to a prespeciﬁed
analytical plan. The primary analysis was by intention to
treat. We also did a per-protocol analysis of the primary
outcome and certain subgroup analyses (those related to
prognostic factors: conﬁrmed falciparum malaria;
severe malaria and less severe malaria; age [children
and adults]; sex; pregnancy [including fetal outcome];
pretreatment with an antimalarial; and with and
without speciﬁed complications of severe malaria—ie,
cerebral malaria, renal failure, jaundice, severe
anaemia, acidosis, haemodynamic shock, and
hyperparasitaemia [deﬁned as 10% parasitaemia]).
For the purposes of the per-protocol analysis, we based
the diagnosis of falciparum malaria on the presence of
asexual P falciparum parasites on the peripheral blood
smear. An analysis of treatment effect in high-mortality
and low-mortality study sites was also prespeciﬁed. For
the severity subgroup analysis, we stratiﬁed patients
retrospectively into two groups: those who fulﬁlled the
criteria for severe malaria with a modiﬁcation of
deﬁnitions used by Hien and colleagues (panel),25 and
those who did not fulﬁl these criteria (ie, less severe
malaria). Since we captured all mortality endpoints and
there were no patients lost to follow up, a comparison of
proportions rather than person-time rates was used in
the analyses. Furthermore, because mortality from
severe malaria is probably dependent on the quality of
care across the different sites, we stratiﬁed comparisons
between proportions by site.
We did analyses with Stata 9 software package
(Statacorp, College Station, TX, USA). We stratiﬁed all
main analyses by study site, and applied tests of
homogeneity of treatment effects. Proportions were
analysed with a stratiﬁed Mantel-Haenszel approach.
We analysed time-to-event variables with Cox
regression analysis.
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Panel: Prospectively speciﬁed criteria used to deﬁne severe
malaria
All measurements and assessments done on entry to study. A
single criterion, in addition to asexual P falciparum parasites on
the peripheral blood ﬁlm, was sufﬁcient.
 Glasgow coma scale 11/15 in adults, or Blantyre coma
scale 3/5 in children 
 Shock, as assessed by admitting physician (low blood
pressure and cool peripheries)
 Blood bicarbonate 15 mmol/L
 Haematocrit 20% and P falciparum parasitaemia
100 000/L
 Visible jaundice and P falciparum parasitaemia
100 000/L
 Blood urea nitrogen 17 mmol/L
 Asexual P falciparum parasitaemia 10%.
 Plasma glucose 2·2 mmol/L
 Respiratory distress (32 breaths per min)
730 assigned and received 
       artesunate
      (633 adults, 97 children) 
4098 patients assessed for 
            eligibility 
2647 excluded 
        73 insufficient clinical criteria
  2354 negative HRP2 test 
     117 adequate previous antimalarial treatment 
     103 refused consent
1461 enrolled and randomised
             (577 Myanmar, 453 Bangladesh, 
             142 India, 289 Indonesia) 
41 blood-smear negative 38 blood-smear negative 
689 analysed 
         (598 adults, 91 children)
693 analysed  
       (592 adults, 101 children) 
731 assigned and received
         quinine 
        (626 adults, 105 children)  
Figure 1: Trial proﬁle
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Role of the funding source
The sponsor of the study had no role in study design,
data collection, data analysis, data interpretation, or
writing of the report. The corresponding author had full
access to all the data in the study and had ﬁnal
responsibility for the decision to submit for publication.
Results
Figure 1 shows the trial proﬁle. We randomised 1461
(730 assigned artesunate, 731 assigned quinine) of
4098 patients assessed for eligibility. Diagnosis of
falciparum malaria was not conﬁrmed by the presence
of parasites on the blood smear in 79 (5%) of these
patients. Patients with unconﬁrmed malaria were
included in the main intention-to-treat analysis, but
were excluded from the per-protocol analysis. Table 1
shows the baseline characteristics of all individuals
randomised. In the artesunate group, 509 (70%)
individuals had severe disease compared with 541
(74%) in the quinine group. Baseline characteristics
and predictors of severity did not differ greatly between
the groups (table 1 and table 2), except for history of
anuria (an excess in the quinine group) and
pretreatment with chloroquine (more in the artesunate
group). History of anuria was subjective, depending on
the recollection of patients or attendant relatives. There
were no differences between the study groups in
concentrations of blood urea nitrogen or levels of
acidosis at admission. Antimalarial pretreatment was
not associated with a difference in the overall severity
of disease. The treatment effects on the main
outcomes were not signiﬁcantly affected by adjustment
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Artesunate (n=730) Quinine (n=731)
Age (years); mean (95% CI) 27·9 (26·8–29·0) 27·9 (26·8–29·0)
Days of fever 5 (3–7, 0–120) 5 (3–7, 0–120)
Days of coma 0 (0–0·75, 0–4) 0·1 (0–1, 1–7)
Physical examination
Weight (kg) 50 (43–55, 9–85) 50 (43–60, 9–100)
Temperature (°C) 38 (37·2–38·9, 35–41·5) 37·9 (37–38·9, 33·8–41·5)
Adult respiratory rate per min 24 (20–32, 12–103) 26 (20–32, 12–68)
Systolic blood pressure (mm Hg) 100 (90–115, 30–200) 100 (90–110, 30–180)
Diastolic blood pressure (mm Hg) 60 (60–70, 0–120) 60 (54–70, 0–100)
Glasgow coma scale (n=1425) 12 (9–15, 3–15) 12 (8–15, 3–15)
Blantyre coma scale (n=36) 4 (3–5, 1–5) 4 (3–5, 0–5)
Investigation
Parasite count (per L); geometric mean (95% CI) 39 850 (33 300–47 700) 31 050 (25 800–37 450)
Sodium (mmol/L) 134 (130–137, 108–159) 134 (130–138, 100–165)
Potassium (mmol/L) 3·9 (3·4–4·3, 2–8·8) 3·8 (3·4–4·3, 2–7·4)
Chloride (mmol/L) 101 (98–104, 77–130) 101 (98–105, 71–128)
Blood urea nitrogen (mmol/L of urea) 9·2 (5·4–17·8, 1·1–104) 10·4 (5·7–21·4, 1·1–86·8)
Haematocrit (%) 30 (22–36, 9–60) 29 (21–36, 5–62)
Haemoglobin (g/L) 100 (71–120, 26–200) 100 (70–120, 80–200)
pH 7·407 (7·352–7·448, 6·5–7·696) 7·4 (7·347–7·45, 6·542–7·582)
paCO2(mm Hg) 33 (28–38, 6–68) 32 (27–37, 7–83)
Total CO2 (mmol/L) 22 (18–25, 2–45) 22 (17–25, 3–42)
Base excess (mmol/L) –3 (–8 to 0, –30 to 22) –4 (–9 to 0, –30 to 12)
Anion gap (mmol/L) 12·5 (0 to 16, –30 to 38) 13 (–1 to 16, –28 to 58)
Data are median (IQR, range) unless otherwise stated.
Table 2: Continuous baseline characteristics
Artesunate (n=730) Quinine (n=731)
Sex
Male 546 (75%) 529 (72%)
Female 184 (25%) 202 (28%)
Child (age 15 years) 97 (13%) 105 (14%)
Pregnant 23 of 133 (17%) 26 of 143 (18%)
Pretreatment with antimalarial drug 167 (23%) 142 (19%)
Pretreatment with quinine 103 (14%) 84 (11%)
Pretreatment with artemisinin derivative 25 (3%) 42 (6%)
Pretreatment with chloroquine 43 (6%) 21 (3%)
Pretreatment with sulphadoxine-pyrimethamine 9 (1%) 10 (1%)
Pretreatment with meﬂoquine 0 5 (1%)
Pretreatment with an effective antimalarial* 125 (17%) 118 (16%)
Severe malaria† 509 (70%) 541 (74%)
Malaria parasites on blood ﬁlm 708 (97%) 716 (98%)
Hyperparasitaemia (10%) 121 (17%) 108 (15%)
Complications on admission
Coma (Glasgow coma scale 11 or 284 (39%) 304 (42%)
Blantyre coma scale 3)
Convulsions 89 (12%) 87 (12%)
Jaundice (clinical) 355 (49%) 349 (48%)
Severe anaemia (haemoglobin 50 g/L) 40/683 (6%) 54/675 (8%)
Shock (clinical) 78 (11%) 92 (13%)
Acidosis (base excess less than –3·3 mmol/L) 308/662 (47%) 334/648 (52%)
Hypoglycaemia (blood glucose 2·2 mmol/L) 8/701 (1%) 17/693 (3%)
Respiratory distress 79 (11%) 96 (13%)
Blackwater fever 20 (3%) 16 (2%)
History of anuria 99 (14%) 135 (18%)
Data are number (%). *Pretreatment with quinine, an artemisinin derivative, or meﬂoquine. Excludes chloroquine and
sulphadoxine-pyrimethamine, which are ineffective throughout this region. †See panel for deﬁnition. 
Table 1: Categorical baseline characteristics
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for either history of anuria or antimalarial
pretreatment. Overall the two treatment groups were
well balanced.
Mortality was 19% (271 of 1461) overall. Mortality in
the artesunate group was 15% compared with 22% in
the quinine group (relative risk 0·69, 95% CI
0·54–0·83; table 3). The result of the analysis on
conﬁrmed malaria (smear positive) cases only was
similar (relative risk 0·69, 0·55–0·85; table 3). Of the
332 smear-positive patients who did not fulﬁl the
criteria for severe malaria on admission, nine died
(3%). Mortality in the patients who fulﬁlled the criteria
for severe malaria was 24% (253 of 1050). 23 and
29 patients in the artesunate and quinine groups,
respectively, died on the day of admission (OR 0·78,
0·45–1·36; p=0·38). Most of the treatment effect
resulted from reduction in mortality after the ﬁrst
24–48 h after entry to the study (table 3, ﬁgure 2).
Overall mortality varied signiﬁcantly between
countries (from 9·3% in Indonesia to 28% in
Bangladesh), but there was no signiﬁcant
heterogeneity in treatment effect (ﬁgure 3). The
absolute risk reduction associated with artesunate
treatment was fairly consistent, ranging from 5% to
9%. Thus the numbers needed to treat to save one life
ranged from 11·1 to 20·2 between the countries.
Ten patients were discharged from hospital with
residual neurological sequelae; seven in the artesunate
group and three in the quinine group (p=0·23). Five
individuals had psychiatric sequelae, four had persisting
problems with balance (one of whom had both
psychiatric sequelae and a tremor), and two had a
hemiparesis. When we combined deaths and
neurological sequelae, there were 114 (16%) adverse
effects in the artesunate group and 167 (23%) in the
quinine group (relative risk 0·70, 0·57–0·86; table 4).
With the exception of hypoglycaemia there were no
serious adverse effects that could be attributed to either
treatment.
Among those who survived, there were no signiﬁcant
differences between the treatment groups for times to
speak, eat, sit, and be discharged (table 3). There was a
signiﬁcant excess of hypoglycaemia after study entry in
the quinine group compared with the artesunate group
(RR 3·2, 95% CI 1·3–7·8; table 3). There were no
differences between the study groups in the incidence
of haemodynamic shock, convulsions, and blackwater
fever, or in the use of supportive therapies (mechanical
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Figure 2: Survival curve of in-hospital mortality
Patients either died in hospital or were discharged well, so all deaths included. To construct plot survival time of all
discharged patients was set to 35 days.
Artesunate (n=730) Quinine (n=731) Mantel-Haenszel stratiﬁed p (stratiﬁed) p for 
OR/hazard ratio [hr] (95% CI) homogeneity 
In-hospital death 107 (15%) 164 (22%) 0·60 (0·45–0·79) 0·0002 0·39
Death within 48 h of entry 61 (8%) 75 (10%) 0·81 (0·57–1·16) 0·25 0·67
Death after 48 h of entry 46 (6%) 89 (12%) 0·48 (0·33–0·70)* 0·0001 0·73
In-hospital death (blood-smear positive) 105 of 689 (15%) 157 of 693 (23%) 0·62 (0·47–0·82) 0·0007 0·29
Neurological sequelae 7 (1%) 3 (1%) 2·3 (0·59–8·8) 0·22 0·34
Combined outcome: in hospital 114 (16%) 167 (23%) 0·63 (0·48–0·82) 0·0007 0·36
death or neurological sequelae
Fetal death 5 of 23 (22%) 5 of 26 (19%) 1·33 (0·28–6·18) 0·72 0·34
Time to discharge (days); median (IQR, range) 5 (4–8, 0–54) 5 (4–8, 0–45) hr 0·93 (0·83–1·04) 0·20 0·77
Time to speak (days); median (IQR, range) 1 (0–2, 0–35) 1 (0–2, 0–21) hr 0·97 (0·84–1·13) 0·73 0·82
Time to eat (days); median (IQR, range) 2 (0–3, 0–21) 2 (0–4, 0–47) hr 0·91 (0·79–1·04) 0·17 0·69
Time to sit (days); median (IQR, range) 2 (0–3, 0–30) 2 (0–3, 0–45) hr 0·91 (0·80–1·05) 0·19 0·82
Convulsions after entry 31 (4%) 43 (6%) 0·70 (0·44–1·12) 0·14 0·09
Shock developing after entry 26 (4%) 36 (5%) 0·72 (0·43–1·21) 0·22 0·59
Hypoglycaemia after entry 6 (1%) 19 (3%) 0·31 (0·12–0·78) 0·009 0·94
Blackwater fever developing after entry 49 (7%) 33 (5%) 1·58 (0·94–2·65) 0·08 0·54
Dialysis after entry 60 (8%) 48 (7%) 1·25 (0·85–1·85) 0·25 0·011
Vasopressor treatment after entry 23 (3%) 24 (3%) 0·92 (0·52–1·64) 0·78 0·28
Mechanical ventilation after entry 26 (4%) 39 (5%) 0·65 (0·39–1·1) 0·11 0·40
Data are number (%) unless otherwise stated. Analysis by intention to treat unless otherwise indicated. Results stratiﬁed by study site. *Excludes patients who died within 48 h.
Table 3: Results by treatment group
Articles
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Number of patients Artesunate mortality Quinine mortality OR (95% CI) p Ratio of OR (95% CI) p for ratio of OR
Blood-smear positive 1382 105 of 689 (15%) 167 of 693 (23%) 0·62 (0·47–0·82) 0·0007 2·84 (0·36–22·2) 0·84
Blood-smear negative 79 2 of 41 (5%) 7 of 38 (18%) 0·22 (0·03–1·68) 0·11
Adult 1259 102 of 531 (16%) 153 of 626 (24%) 0·61 (0·46–0·81) 0·0005 1·42 (0·41–4·85) 0·71
Child 202 5 of 97 (5%) 11 of 105 (11%) 0·43 (0·13–1·42) 0·15
Male 1075 78 of 546 (14%) 123 of 529 (23%) 0·56 (0·41–0·77) 0·0003 0·81 (0·43–1·53) 0·26
Female 386 29 of 184 (16%) 41 of 202 (20%) 0·69 (0·40–1·21) 0·19
Pregnant female 49 2 of 23 (9%) 3 of 26 (12%) 0·75 (0·09–6·41) 0·79 1·11 (0·12–10·25) 0·54
Non-pregnant female 337 27 of 161 (19%) 38 of 176 (22%) 0·68 (0·38–1·20) 0·18
Pre-treatment 309 19 of 167 (11%) 37 of 142 (26%) 0·40 (0·21–0·75) 0·003 0·6 (0·3–1·21) 0·08
No pre-treatment 1152 88 of 563 (16%) 127 of 529 (22%) 0·66 (0·49–0·9) 0·008
Low mortality site 783 34 of 397 (9%) 59 of 386 (15%) 0·53 (0·34–0·83) 0·005 0·83 (0·47–1·47) 0·26
High mortality site 678 73 of 333 (22%) 105 of 345 (30%) 0·64 (0·45–0·91) 0·01
“Severe malaria” 1050 101 of 509 (20%) 152 of 541 (28%) 0·65 (0·48–0·87) 0·003 1·58 (0·56–4·58) 0·81
Not “severe malaria” 411 6 of 221 (3%) 12 of 190 (6%) 0·41 (0·15–1·11) 0·07
Cerebral malaria* 563 82 of 272 (30%) 108 of 291 (37%) 0·71 (0·49–1·02 0·06 1·61 (0·87–2·98) 0·93
Not cerebral malaria* 820 23 of 418 (6%) 49 of 402 (12%) 0·44 (0·27–0·73) 0·001
Renal failure* 282 51 of 136 (38%) 76 of 146 (52%) 0·51 (0·31–0·84) 0·007 0·74 (0·39–1·41) 0·18
No renal failure* 1026 47 of 525 (9%) 65 of 501 (13%) 0·69 (0·46–1·02) 0·06
Unspeciﬁed* 74 7 of 28 (25%) 16 of 46 (35%) 0·66 (0·21–2·05) 0·47
Jaundiced* 674 63 of 338 (19%) 85 of 336 (25%) 0·69 (0·47–1·01) 0·05 1·22 (0·7–2·15) 0·76
Not jaundiced* 708 42 of 351 (12%) 72 of 357 (20%) 0·57 (0·37–0·86) 0·007
Severe anaemia* 318 18 of 157 (16%) 29 of 161 (18%) 0·6 (0·34–1·43) 0·32 0·96 (0·46–1·96) 0·45
No severe anaemia* 1011 81 of 508 (16%) 118 of 503 (24%) 0·63 (0·46–0·86) 0·004
Unspeciﬁed* 53 6 of 24 (25%) 10 of 29 (35%) 0·81 (0·24–2·74) 0·73
Acidosis* 613 77 of 294 (26%) 121 of 319 (38%) 0·58 (0·41–0·82) 0·002 0·83 (0·37–1·84) 0·32
No acidosis* 642 14 of 338 (4%) 18 of 304 (6%) 0·7 (0·34–1·43) 0·32
Unspeciﬁed* 127 14 of 57 (25%) 18 of 70 (26%) 1·05 (0·45–2·43) 0·91
Shock* 165 12 of 75 (16%) 27 of 90 (30%) 0·35 (0·15–0·85) 0·02 0·54 (0·21–1·37) 0·1
Not shocked* 1217 93 of 614 (15%) 130 of 603 (22%) 0·66 (0·49–0·87) 0·006
Hyperparasitaemia* 229 28 of 121 (23%) 57 of 108 (53%) 0·26 (0·14–0·49) 0·0001 0·34 (0·17–0·69) 0·001
No hyperparasitaemia* 1153 77 of 568 (14%) 100 of 585 (17%) 0·77 (0·55–1·07) 0·11
All analyses stratiﬁed by study site, and done by intention to treat unless otherwise indicated.29 *Done on conﬁrmed malaria (smear-positive) subset. 
Table 4: Results of prespeciﬁed subgroup analyses
Bangladesh
India
Indonesia
Myanmar
Myanmar, 1992
Overall
SEAQUAMAT
Thailand, 2003
Vietnam, 1997
Vietnam, 1992
Number of 
patients
453 52/222 (23%) 75/231 (32%) 0·03
0·5
0·08
0·01
0·0002
0·00005
0·22
0·73
0·36
0·02
15/70 (21%)
9/143 (6%)
31/295 (11%)
107/730 (15%)
7/59 (12%)
4/37 (11%)
5/31 (16%)
2/24 (8%)
125/881 (14%) 212/917 (23%)
23/67 (34%)
0·1 0·3
Artesunate better Quinine better
OR (95% Cl)
0·5 0·7 1·0 1·5 2·0
8/30 (27%)
5/35 (14%)
12/54 (22%)
164/731 (22%)
52/282 (18%)
18/146 (12%)
19/72 (26%)142
289
577
1461
113
72
61
91
1798
Artesunate
mortality
Quinine
mortality
p
Figure 3: Forest plot of mortalities comparing parenteral quinine and artesunate in treatment of severe malaria in SEAQUAMAT and previously published
studies23,26–28
Size of boxes proportional to number of events in individual trial and thus contribution to overall effect. Diamond=summary stratiﬁed OR and 95% CI.
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ventilation, vasopressor support, and dialysis). There
was signiﬁcant heterogeneity in the use of dialysis by
study drug, which was restricted to Myanmar, and
results from a small excess in dialysis at one study site
in patients randomised to artesunate compared with
three other study sites in the country where more
quinine patients were appropriately dialysed (there are
no dialysis facilities at the other three sites). 
Two centres were discontinued during the trial; they
recruited 155 patients of whom 13 died. Subgroup
analyses were done in accordance with the prespeciﬁed
analysis plan (table 4). With the exception of
hyperparasitaemic patients, in every case the ORs for
the treatment effect did not differ signiﬁcantly between
the subgroups. 
There were 202 children (younger than age 15 years)
in the study of whom 89 were aged younger than
6 years. The overall mortality in children was 8% (16 of
202). Although the treatment effect in favour of
artesunate did not differ signiﬁcantly from that in
adults, by itself it was not signiﬁcant in children. The
treatment effect associated with artesunate was as good
in patients who had received effective antimalarial
treatment before admission as in those who had not
(ratio of ORs 0·6, 95% CI 0·3–1·21). Pretreatment
included quinine in 187 patients, an artemisinin
derivative in 67, chloroquine in 64, and sulphadoxine-
pyrimethamine in 19 (some patients received more
than one drug). Post-hoc (not pre-speciﬁed) analyses of
pretreatment drug subgroups revealed no signiﬁcant
patterns with respect to the treatment effect.
Patients with hyperparasitaemia (admission
parasitaemia 10%) had a signiﬁcantly greater
treatment effect with artesunate than non-
hyperparasitaemic patients (ratio of ORs 0·34,
0·17–0·69, p=0.001). 
Discussion
Our ﬁndings in this large multicentre trial show that
parenteral artesunate reduces mortality in patients
with severe malaria by over a third compared with
quinine. Although there were considerable differences
in the intensive-care support available between the trial
sites, this large reduction in mortality was consistent
across countries and in all prospectively deﬁned
subgroups. Randomisation was adequate, and there
were no signiﬁcant confounding factors. The beneﬁts
of artesunate were evident mainly after the ﬁrst day of
treatment. This ﬁnding suggests that the lethal
pathological processes in falciparum malaria that
killed some of our patients shortly after admission
were not preventable by improved antimalarial
treatment, but after 24–48 h on treatment a clear and
large advantage of artesunate emerged. This beneﬁt
presumably derives from greater parasiticidal activity.
The main pharmacodynamic difference between
artesunate and quinine is the much broader stage-
speciﬁcity of action of the artemisinin compounds.30
Artesunate kills circulating ring-stage parasites, which
can then be removed by the spleen, whereas quinine
does not.31–33 Both artesunate and quinine are active
against the more pathological cytoadhering stages that
sequester in the venules and capillaries of vital organs.
Thus, artesunate prevents maturation of the younger
parasite stages and thereby prevents sequestration,34
which reduces consequent microcirculatory
obstruction.26 This method of action is consistent with
the ﬁnding that the difference in mortality between the
two groups was greatest in those patients with high
parasitaemias—ie, those for whom prevention of
sequestration would be expected to provide the greatest
beneﬁt. The large reduction in mortality associated
with artesunate treatment emphasises the central
quantitative role of parasitised erythrocyte
sequestration in the pathology of malaria, and it argues
against a major role for hypothetical immuno-
pathological processes that are quantitatively unlinked
to the sequestered parasite biomass.
In the 1980s and early 1990s artemotil (arteether),
and later artemether, were strongly supported over
artesunate by WHO-TDR. This preference was
declared before evidence of clinical beneﬁt or data on
human pharmacokinetics became available. In a meta-
analysis of randomised trials,15 which enrolled
1919 patients with severe malaria, artemether did not
reduce mortality signiﬁcantly when compared with
quinine. In the prospectively deﬁned subgroup of
adults in southeast Asia there was a signiﬁcantly lower
mortality in the artemether recipients, which was not
seen in African children. This ﬁnding was not
sufﬁcient to change treatment policies. In our trial,
done mainly in adults, artesunate reduced the
mortality of severe malaria by over a third compared
with quinine. The size and direction of the treatment
effect is similar to that seen in the much smaller
previously published trials that compared artesunate
and quinine, and a combined meta-analysis of these
and the current trial gave an overall mortality OR in
favour of artesunate of 0·57 (0·45–0·73), p=0·00005
(ﬁgure 3).24,27,28,35 The most likely explanation for the
much larger reduction in mortality with artesunate
than with artemether is the pronounced difference in
the pharmacokinetic properties of the two artemisinin
compounds. Artemether is an oil-based formulation
that is absorbed slowly and erratically after
intramuscular injection, whereas both artesunate and
quinine are water soluble and are absorbed rapidly and
reliably after intramuscular injection,16–22,36 and both
can be given intravenously. Thus the pharmaco-
dynamic advantage of artemether over quinine might
have been offset by its poor absorption kinetics after
intramuscular injection.
In our study, quinine was associated with hypogly-
caemia. The incidence of reported hypoglycaemia after
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starting treatment was relatively low by comparison
with other series where blood glucose has been actively
monitored,11,25 and is probably an underestimate since
clinical signs of hypoglycaemia are often absent in
severe malaria. No other severe adverse effects could
be attributed to either drug.
This trial was done mainly in adults in areas of low
and unstable transmission. The results cannot be
extrapolated directly to the treatment of severe malaria
in children in areas of higher transmission. The
clinical evolution of severe malaria is more rapid, and
the range of vital organ dysfunction is different in
children than in adults.37 Furthermore, a greater
proportion of the total mortality occurs within the ﬁrst
day after the start of treatment in children than in
adults, providing less opportunity for a better
antimalarial to save lives. In the artemether versus
quinine trials,15 no beneﬁt of artemether was evident in
African children. This ﬁnding suggests that the
superiority of artesunate over quinine in severe
malaria might be less obvious in African children. A
trial with similar design to ours has just begun in
Africa, the aim of which is to provide a deﬁnitive
answer to this question.
For adults with severe malaria, artesunate should be
the treatment of choice. The drug is more effective
than quinine, is simple to administer, and is safe. The
only serious adverse effect that has been clearly linked
with artesunate is a rare type-1 hypersensitivity
reaction, which arises in about one in 3000 treated
patients.38 By contrast, quinine is locally toxic
(particularly as the acidic dihydrochloride salt) after
intramuscular injection (often causing sciatic nerve
damage), cannot be given by bolus intravenous
injection, requires three-times daily administration, is
associated with potentially serious hypoglycaemia, and
is less effective than artesunate. Unfortunately, despite
20 years of use in east Asia, there is still no generally
available formulation of parenteral artesunate made to
Good Manufacturing Practices standards. Quality
assured, affordable parenteral artesunate should be
made widely available in malaria endemic areas as a
matter of urgency.
Contributors
The coordinating committee designed the study; all investigators in
Bangladesh, Myanmar, India, and Indonesia did the trial with support
from the teams in Thailand; all investigators and the coordinating
committee reviewed and discussed the results; the writing committee
did the data analyses and prepared the report, which was then reviewed
by all investigators.
SEAQUAMAT group
Bangladesh—Prof M Abul Faiz, Emran Bin Yunus,
M Ridwanur Rahman, Prof Faridul Islam, Prof M Gofranul Hoque,
Mahatab Uddin Hasan, Rasheda Samad, and research assistants and
study nurses. 
Myanmar—Soe Aung, Soe Thein, Prof Marlar Than, Prof Ye Thwe,
Prof Khin Mae Ohn, San Hla, Saw Lwin, Ye Htut, Khin Lin,
Myat Phone Kyaw, Ne Win, Win Ne Aung, Myint Win, Aung Zaw Oo,
Zaw Aung, Ohnmar Myint Shein, Mar Mar Kyi, Win Win Myint,
724 www.thelancet.com Vol 366   August 27, 2005 
Khin Phyu Pyar, Kyaw Nyein, and Kyu Kyu Win. Coordinated by the
Ministry of Health, Union of Myanmar, and the Department of Medical
Research, Yangon. 
India—Saroj K Mishra, Sanjib Mohanty, Rajya Bardhan Pattnaik,
Sanjay K Acharya, Anita Mohanty, and Devendranath Mohapatra. 
Indonesia—Emiliana Tijtra, Prof Nicholas Anstey, Ric Price,
Tjandra Handoyo, Dekrit Gampamola, Enny Kenangalem,
Denny Takaendengan, Hardiyanto, Ardi Lampat, and Paul Harijanto.
Coordinated by the National Institute of Health Research and
Development, Ministry of Health, Republic of Indonesia, and the
Menzies School of Health Research and Charles Darwin University,
Darwin, Australia. 
Clinical, laboratory, statistical, and logistic support—Wellcome Unit and
Shoklo Malaria Research Unit, Faculty of Tropical Medicine, Mahidol
University, Bangkok, Thailand: Arjen Dondorp, François Nosten,
Nick Day, Kasia Stepniewska, Prakaykaew Tipmanee, Sam Douthwaite,
Kamolrat Silamut, and Stephane Proux. 
Coordinating committee—Arjen Dondorp, François Nosten, Nick Day,
Kanchana Pongsawat, and Prof Nick White (chair).
Writing committee—Arjen Dondorp, François Nosten,
Kasia Stepniewska, Nick Day, and Prof Nick White.
Data and safety monitoring committee—David Lalloo, Sarah Walker, and
Prof Tim Peto (chair).
Conﬂict of interest statement
N J White is chairman, and M A Faiz and E Tijtra are members of the
WHO antimalarial treatment guidelines committee. None of the other
triallists or members of the writing committee has any conﬂict of
interest. 
Acknowledgments
We thank the directors and staff of the trial hospitals, and the doctors,
research nurses, and research assistants for their help;
Prof Kyaw Myint, Minister of Health, Myanmar, for his support;
Kyaw Win, for his advice and help in initiating this study; and
Marja Dondorp-Schilstra for designing the database and
Prof Richard Peto for advice. This trial was funded by a grant from the
Wellcome Trust, and was coordinated as part of the Wellcome Trust-
Mahidol University-Oxford Tropical Medicine Research Programme
funded by the Wellcome Trust of Great Britain.
References
1 Pukrittayakamee S, Supanaranond W, Looareesuwan S,
Vanijanonta S, White NJ. Quinine in severe falciparum malaria:
evidence of declining efﬁcacy in Thailand. Trans R Soc Trop Med
Hyg 1994; 88: 324–27.
2 Rashid R, Faiz MA, Rahman MR, et al. Quinine resistant
falciparum malaria in Chittagong: a case report. Bangladesh J Med
2000; 11: 132–33.
3 Clyde DF, Miller RM. Treatment of falciparum malaria caused by
strains resistant to quinine. JAMA 1970; 213: 2041. 
4 Jaroovesma N, Harinasuta T, Muangmanee L. Recrudescence, poor
response or resistance to quinine of falciparum malaria in
Thailand. Southeast Asian J Trop Med Public Health 1974; 5: 504–09.
5 Giboda M, Denis MB. Response of Kampuchean strains of
Plasmodium falciparum to antimalarials: in vivo assessment of
quinine and quinine plus tetracycline; multiple drug resistance in
vitro. J Trop Med Hyg 1988; 91: 205–11.
6 Looareesuwan S, Charoenpan P, Ho M, White NJ, Karbwang J,
Bunnag D, Harinasuta T. Fatal Plasmodium falciparum malaria after
an inadequate response to quinine treatment. J Infect Dis 1990; 161:
577–80. 
7 WHO. Severe and complicated malaria. Trans R Soc Trop Med Hyg
1990; 84 (Suppl 2): 1–65.
8 WHO. Severe and complicated malaria. Trans R Soc Trop Med Hyg
2000; 94 (Suppl 1): 1–90. 
9 White NJ. The treatment of malaria. N Engl J Med 1996; 335:
800–06.
10 Yen LM, Dao LM, Day NP, et al. Role of quinine in the high
mortality of intramuscular injection tetanus. Lancet 1994; 344:
786–87. 
11 White NJ, Warrell DA, Chanthavanich P, et al. Severe hypoglycemia
and hyperinsulinemia in falciparum malaria. N Engl J Med 1983;
309: 61–66.
Articles
12 China Cooperative Research Group on qinghaosu and its
derivatives as antimalarials. Antimalarial studies on Qinghaosu.
Chin Med J 1979; 92: 811–16.
13 Li GQ, Guo XB, Jin R, Wang ZC, Jian HX, Li ZY. Clinical studies
on treatment of cerebral malaria with qinghaosu and its
derivatives. J Tradit Chin Med 1982; 2: 125–30.
14 International Artemisinin Study Group. Artesunate combinations
for treatment of malaria: a meta-analysis. Lancet 2004; 363: 9–17.
15 Artemether-Quinine Meta-analysis Study Group. A meta-analysis
using individual patient data of trials comparing artemether with
quinine in the treatment of severe falciparum malaria.
Trans R Soc Trop Med Hyg 2001; 95: 637–50. 
16 Faiz MA, Rahman E, Hossain MA, et al. A randomized controlled
trial comparing artemether and quinine in the treatment of
cerebral malaria in Bangladesh. Indian J Malariol 2001; 38: 9–18. 
17 Murphy SA, Mberu E, Muhia D, et al. The disposition of
intramuscular artemether in children with cerebral malaria; a
preliminary study. Trans R Soc Trop Med Hyg 1997; 91: 331–34. 
18 Silamut K, Newton PN, Teja-Isavadharm P, et al. Artemether
bioavailability after oral or intramuscular administration in
uncomplicated falciparum malaria. Antimicrob Agents Chemother
2003; 47: 3795–98. 
19 Mithwani S, Aarons L, Kokwaro GO, et al. Population
pharmacokinetics of artemether and dihydroartemisinin following
single intramuscular dosing of artemether in African children with
severe falciparum malaria. Br J Clin Pharmacol 2004; 57: 146–52. 
20 Hien TT, Davis TM, Chuong LV, et al. Comparative
pharmacokinetics of intramuscular artesunate and artemether in
patients with severe falciparum malaria. Antimicrob Agents
Chemother 2004; 48: 4234–39.
21 Ilett KF, Batty KT, Powell SM, et al. The pharmacokinetic
properties of intramuscular artesunate and rectal
dihydroartemisinin in uncomplicated falciparum malaria.
Br J Clin Pharmacol 2002; 53: 23–30. 
22 Nealon C, Dzeing A, Muller-Romer U, et al. Intramuscular
bioavailability and clinical efﬁcacy of artesunate in Gabonese
children with severe malaria. Antimicrob Agents Chemother 2002; 6:
933–39.
23 Brockman A, Price RN, van Vugt M, et al. Plasmodium falciparum
antimalarial drug susceptibility on the northwestern border of
Thailand during ﬁve years of extensive artesunate-meﬂoquine use.
Trans R Soc Trop Med Hyg 2000; 94: 537–44. 
24 Newton P, Angus BJ, Chierakul W, et al. A randomised
comparison of intravenous artesunate or quinine in the treatment
of severe falciparum malaria. Clin Infect Dis 2003; 37: 7–16. 
25 Hien TT, Day NPJ, Phu NH, et al. A controlled trial of artemether
or quinine in Vietnamese adults with severe falciparum malaria.
N Engl J Med 1996; 335: 76–83. 
26 Dondorp AM, Kager PA, Vreeken J, White NJ. Abnormal blood
ﬂow and red blood cell deformability in severe malaria.
Parasitol Today 2000; 16: 228–32.
27 Win K, Than M, Thwe Y. Comparison of combinations of
parenteral artemisinin derivatives plus oral meﬂoquine with
intravenous quinine plus oral tetracycline for treating cerebral
malaria. Bull World Health Organ 1992; 70: 777–82.
28 Hien TT, Arnold K, Vinh H, et al. Comparison of artemisinin
suppositories with intravenous artesunate and intravenous quinine
in the treatment of cerebral malaria. Trans R Soc Trop Med Hyg
1992; 86: 582–83. 
29 Altman DG, Bland MJ. Interaction revisited; the difference
between two estimates. BMJ 2003; 326: 219.
30 ter Kuile F, White NJ, Holloway P, Pasvol G, Krishna S.
Plasmodium falciparum: in-vitro studies of the pharmacodynamic
properties of drugs used for the treatment of severe malaria.
Exp Parasitol 1993; 76: 86-95. 
31 Gravenor MB, van Hensbroek MB, Kwiatkowski D. Estimating
sequestered parasite population dynamics in cerebral malaria.
Proc Natl Acad Sci USA 1998; 95: 7620–24. 
32 Watkins WM, Woodrow C, Marsh K. Falciparum malaria:
differential effects of antimalarial drugs on ex vivo parasite viability
during the critical early phase of therapy. Am J Trop Med Hyg 1993;
49: 106–12.
33 Chotivanich K, Udomsangpetch R, McGready R, et al. The central
role of the spleen in malaria parasite clearance. J Infect Dis 2002;
185: 1538–41.
34 Udomsangpetch R, Pipitaporn B, Krishna S, et al. Antimalarial
drugs reduce cytoadherence and rosetting of Plasmodium
falciparum. J Infect Dis 1996; 173: 691–98.
35 Cao XT, Bethell DB, Pham TP, et al. Comparison of artemisinin
suppositories, intramuscular artesunate and intravenous quinine
for the treatment of severe childhood malaria. Trans R Soc Trop
Med Hyg 1997; 91: 335–42.
36 White NJ. Optimal regimens of parenteral quinine. Trans R Soc
Trop Med Hyg 1995; 89: 462–63.
37 van Hensbroek MB, Onyiorah E, Jaffar S, et al. A trial of
artemether or quinine in children with cerebral malaria.
N Engl J Med 1996; 335: 69–75. 
38 Leonardi-Nield E, Gilvary G, White NJ, Nosten F. Severe allergic
reactions to oral artesunate: a report of two cases. Trans R Soc Trop
Med Hyg 2001; 95: 182–83. 
www.thelancet.com Vol 366   August 27, 2005  725
